AMYVID
LOE Approachingflorbetapir f 18
NDAINTRAVENOUSSOLUTIONPriority Review
Approved
Apr 2012
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Data completeness
3/8 — Basic
Priority Review
AMYVID (florbetapir f 18) is positron emitting activity [moa]. First approved in 2012.
Drug data last refreshed 12h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AMYVID (florbetapir F 18) is a positron-emitting radioactive diagnostic agent administered intravenously for PET imaging. It binds to amyloid-beta plaques in the brain, enabling detection of amyloid pathology in patients with cognitive impairment or suspected Alzheimer's disease. The agent facilitates early diagnosis and risk stratification in neurodegenerative disease management.
LOE Approaching10mo to LOE
Product faces patent expiration in <1 year (April 2027), signaling transition to defending market share against generics and managing commercial team right-sizing.
Mechanism of Action
Positron Emitting Activity
Pharmacologic Class:
Radioactive Diagnostic Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in less than a year — expect lifecycle management and generic defense hiring
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.